

Connecticut Urology Society


Annual Educational Meeting

Wednesday, November 13, 2024

8:00am - 4:45pm

Program

Connecticut
Urology
Society



CONNECTICUT UROLOGY SOCIETY
Educational Meeting
Wednesday November 13, 2024 • 8:00am - 4:45pm



- 8:00 **Registration**
- 8:30 **Opening Remarks** - Guy Manetti, MD, President
- 8:45 **Business Meeting** - Guy Manetti, MD, President
- 9:15 **Surgical management of high-risk and metastatic prostate cancer** – Isaac Kim, MD
Objectives: 1. Discuss surgery in managing high-risk prostate cancer. 2. Discuss neoadjuvant ADT to downstage prostate cancer. 3. Discuss cytoreductive prostatectomy in men with de novo metastatic prostate cancer.
- 10:00 Coffee, tea and pastries with vendors
- 10:30 **Cardiac Risk in Men with Erectile Dysfunction: What is the Urologist's Role?** – Jared Bieniek, MD
Objectives: 1. Understand the link between erectile dysfunction and cardiovascular disease. 2. Recognize risk factors for men presenting with new ED that may predict higher CVD risk. 3. Be able to describe behavioral/dietary recommendations to optimize both erectile and cardiac health and identify your own preventive cardiology colleagues.
- 11:00 **Contemporary management of non-muscle invasive bladder cancer** – Adam Feldman, MD
Objectives: 1. Discuss evidence based and guideline directed management of NMIBC.
- 11:30 **AUA Updates** – Art Tarantino, MD
Objectives: 1. To review some of the National patient advocacy advances and discuss national policies on patient care.
- 11:45 Lunch with Vendors
- 12:15 Product Theater
- 1:00 **Artificial Intelligence in Urology: Opportunities, Barriers, and Risks** – Boris Gershman, MD
Objectives: 1. To understand the current and potential future applications of artificial intelligence in urology. 2. To understand the barriers to development of artificial intelligence tools, and the risks associated with their utilization.
- 1:45 **The Status of the Medical Malpractice Climate in Connecticut- Strategies to Mitigate Risk** – Joyce Lagnese, JD
Objectives- To understand the medical risk climate currently in Connecticut and how this affects patient management, documentation and outcomes.
- 2:30 **Trimodality therapy for muscle invasive bladder cancer** – Adam Feldman, MD
Objectives: 1. The talk will be a review of trimodality therapy for muscularis propria invasive urothelial carcinoma of the bladder. We will focus on the Urologist's critical role in patient selection, aggressive TURBT, as well as the continued role of the urologist in repeat cystoscopic assessments and ongoing surveillance. We will review the coordinated multidisciplinary approach for bladder preservation, need for early salvage cystectomy when indicated, as well as management of non-muscle invasive recurrences. We will review potential toxicities and quality of life associated with bladder sparing therapy versus cystectomy and will review the most recent data on oncologic outcomes as compared to radical cystectomy.
- 3:00 Coffee break with vendors
- 3:30 **Bipartisan Healthcare 2025**
– Senator Jeff Gordon, MD
- 3:45 **Coding- How to document and prepare for Audits**
– Robin Linker, CHCRA, CHCA, CHCAS, CPC-I, CPC-P, CCS-P, MCS-P, COC, CHC
Objectives: 1. To understand common documentation errors and identify areas in need of improvement Within the medical record 2. To review member need gap questions in coding and identify proper documentation and coding
- 4:45 Certificates – Raffle in Wagon Room Lounge

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CSEP and the CT UROLOGY SOCIETY.

CSEP is accredited by the ACCME to provide continuing medical education for physicians. CSEP designates this educational activity for a maximum of 5.0 AMA PRA Category I Credit(s)™ toward the AMA Physicians Recognition Award.

Each physician should claim only those hours of credit that he/she spent in the activity.

**Jared Bieniek, MD**

Hailing from Pennsylvania, Dr. Bieniek earned his BS in Bioengineering from Pennsylvania State University in 2005 and graduated from the University of Pittsburgh School of Medicine in 2009. He completed Urology residency at Geisinger Medical Center, followed by a fellowship in Male Reproductive Medicine at University of Toronto. Currently, he serves as the Medical Director of Men's Health for the Tallwood Urology & Kidney Institute at Hartford HealthCare. Dr. Bieniek actively participates in local and national professional societies, including the American Society of Reproductive Medicine (chair, patient education committee) and the Sexual Medicine Society of North America (young urologist committee). His research focuses on mental health in men's health, DEI in sexual health education, cardiovascular implications of erectile dysfunction, and the impact of AI on urologic care. He has published extensively and remains an active reviewer for manuscripts on male fertility, sexual health, and medical devices.

**Adam S. Feldman, MD, MPH**

Dr. Adam S. Feldman is a Urologic Oncologist at the Massachusetts General Hospital and Associate Professor of Surgery at Harvard Medical School. He is Program Co-Director of The Combined Harvard Medical School Urologic Oncology Fellowship Program and Associate Chair for Research for the Department of Urology at MGH. He completed his residency in Urology in 2006 and subsequently completed his fellowship in Urologic Oncology in June 2008. Dr. Feldman focuses his clinical practice in the treatment of urothelial cancer, prostate cancer, kidney cancer and other genitourinary malignancies. He focuses his research interests on translational and clinical research in urothelial, prostate, and kidney cancers. He received a Prostate Cancer Foundation Young Investigator Award for his work in novel biomarkers in prostate cancer and was awarded a Physician Research Training Award by the Department of Defense. He has since received several federally funded, foundation and industry sponsored research grants for his work in biomarker development and metabolomics in genitourinary malignancies.

**Boris Gershman, MD**

Dr. Gershman is a urologic oncologist in the Division of Urologic Surgery at Beth Israel Deaconess Medical Center and an Associate Professor of Surgery at Harvard Medical School. He completed residency training at the Massachusetts General Hospital followed by a Society of Urologic Oncology (SUO) fellowship at Mayo Clinic. His clinical practice focuses on the management of urologic malignancies, including bladder, prostate, and kidney cancer. Dr. Gershman has a broad research interest in comparative effectiveness and health services research within urologic oncology, with a particular focus on causal inference from observational datasets.

**Isaac Y. Kim, MD, PhD, MBA** *Chair and Professor of Urology Yale School of Medicine*

Dr. Isaac Kim is the current Chair of the Department of Urology at Yale School of Medicine. He joined Yale in September of 2021 with the vision of building a department that will improve the care of urology patients through innovative clinical trials and cutting-edge basic research. He specializes in the treatment, management, and prevention of prostate cancer. He is an expert in minimally invasive robotic surgery and has completed more than 2,200 robotic surgeries for prostate cancer. Dr. Kim's surgical focus has been on advanced and metastatic prostate cancer, as well as recurrent disease after radiation. Dr. Kim's research is focused on mechanisms of treatment resistance and specifically immunosuppressive factors produced by prostate cancer cells. He also has a strong interest in inflammation in prostate cancer and the role of surgery in men with advanced or metastatic prostate cancer.

**Robin Linker, CHCRA, CHCA, CHCAS, CPC-I, CPC-P, CCS-P, MCS-P, COC, CHC**

As a leading expert with over 30 years in healthcare, Robin has provided consulting and education in most areas of practice management, compliance, correct coding and billing practices. She is the Executive Director of Operations and Auditing for the Association of Health Care Auditors and Educators (AHCAE) and is CEO of Robin Linker & Associates, Inc., a nationally known healthcare consulting firm, located in Aurora, Colorado. Robin is the past Director of Education and Technical Development for the American Academy of Professional Coders (AAPC) where she wrote and presented numerous specialty related coding and training programs nationwide. She has been a frequent guest speaker for AHIMA, AAPC, HFMA, HCCA as well as numerous medical societies, associations and other healthcare organizations.

Robin assists various healthcare venues with expertise in compliance, coding, auditing, and as an expert case witness. She is an experienced IRO assisting providers and organizations under mandated OIG Corporate Integrity Agreements. As a co-author and presenter of the AMA's ICD-10-CM Workshops and CPT Coding Updates Workshops, she is a true advocate in the healthcare industry, Robin has dedicated her career to her clients by increasing industry awareness and contributing to systems improvement. She is a member of the National Speakers Association and has provided thousands of educational and keynote presentations throughout the United States and on occasion, internationally over the past 20 years.

With a strong background in research and development, Robin has a knack for the technical side of healthcare, evaluating, developing and contributing to cutting edge technology. She is the coauthor of college curriculum, "Understanding Medical Coding: A Comprehensive Guide" currently in its 4th edition, and is currently writing a book for the AMA. Robin enjoys active participation with her audience and a touch of humor in her workshops.

**Art Tarantino, MD**

Dr. Arthur Tarantino is a past president of the CT Urology Society and sits on the board of the AUA. Dr. Tarantino has achieved many accomplishments at the AUA including completed his 1-year term as the Chair of the State Advocacy Committee. He also created Proclamation and Telehealth Toolkits; helped with the development of Telehealth PowerPoint, State Legislation Support Letter, AUA Telehealth Strategy and AUA Talking Points; and created the Grant Program, which provided monetary assistance to the states/sections to advocate for legislation, fund advocacy meetings and other programs which are advocacy related. He also expanded the State Advocacy Committee, adding 2 representatives from each AUA Section and ensuring diversity.



Joyce Lagnese, JD

Ms. Lagnese is one of the founding principals of the Hartford Law firm of DanaherLagnese, PC, where she serves as head of the Medical Malpractice Defense Unit. She is a high honors graduate from the State University of New York and obtained her law degree with honors in 1980 from Hofstra University School of Law. Her practice concentration is high exposure medical practice defense litigation. For over three decades, she has defended medical malpractice cases throughout Connecticut on behalf of physicians from every medical specialty, and has successfully tried to verdict a large number of medical malpractice cases including claims of wrongful death and permanent injury. Her practice also includes representation of medical practitioners and institutions in administrative proceedings before the Connecticut Department of Public Health.

Ms. Lagnese has been an invited lecturer and Keynote Speaker to various local and regional medical societies, physicians organizations and hospitals on medico-legal topics and is co-author of a textbook on Connecticut Medical Malpractice. She has also been an advocate in the Connecticut State Legislature for malpractice tort reform.

In my position to control the content of this education activity I have reviewed all speakers and planners financial disclosures disclosures of all relevant financial relationships with any commercial interest and found that this program has no conflicts of interest. The ACCME defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest

- Guy Manetti, MD

submitted to Executive Committee and CSEP 8-6-24.

In my position to control the content of this education activity I have reviewed all speakers and planners financial disclosures disclosures of all relevant financial relationships with any commercial interest and found that this program has no conflicts of interest. The ACCME defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest

-Debbie Osborn, Exec Director 8-6-24

Outcome Measurements

Name: _____

- 1. Has this symposium changed the way you will care for patients? Yes No
- 2. Do you believe this symposium will have a positive effect on patient surgical or clinical outcomes?
 Yes No
- 3. Can you offer other speakers or topics that will provide information to improve clinical outcomes at the next meeting? Yes No _____

4. How has this symposium changed the way you will care for patients and what are you going to change?

Mission Statement

The mission statement of the Connecticut Urology Society is to serve, represent and advance the science and the ethical practice of Urology in the State of Connecticut. Our target audience includes urologists and their staff, including, nurses, PAs, medical assistants, scribes, office managers and front office staff.

The Society promotes excellence in patient care and education in Urology through the sponsorship of an Annual Scientific meeting. The Connecticut Urology Society is dedicated to providing communication and fellowship to the members of the Urologic Community in Connecticut through these meetings.

The programs are an opportunity for urologists to identify and discuss critical issues facing their profession and are designed to meet the clinical and educational needs of its members and the objectives set forth by the CT Urology Executive Board. Specific competency, performance and patient outcomes will be proposed by speakers and evaluated by participants.

(approved 10/11/18 Executive Committee)

CSEP ensures that all decisions related to the planning, faculty selection, delivery, and evaluation of accredited education are made without any influence or involvement from the owners and employees of an ineligible company. In addition, CSEP ensures that the Accredited education is free of marketing or sales of products or services and that all faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. CSEP will not share the names or contact information of learners with any ineligible company or its agents without the explicit consent of the individual learner.

Competency Questions

Artificial Intelligence in Urology: Opportunities, Barriers, and Risks- Boris Gershman, MD

- Question 1. All of the following represent potential areas of application for artificial intelligence in urology in the near future EXCEPT:
- Clinical care
 - Research
 - Practice management
 - Education
 - Supervision
- Question 2. All of the following represent potential barriers to the development or dissemination of artificial intelligence tools in urology EXCEPT:
- Data availability
 - External validation
 - End-user interest
 - Regulatory requirements
 - End-user trust

Contemporary management of non-muscle invasive bladder cancer – Adam Feldman, MD

- Question 1. What is the optimal treatment per AUA Guidelines for an otherwise healthy 65yo male patient with cT2 muscle-invasive urothelial carcinoma of the bladder (no carcinoma in situ, no hydronephrosis)?
- Radical cystectomy (with neoadjuvant chemotherapy)
 - Bladder preserving trimodality therapy with chemoradiation
 - Radical TURBT
 - A or B
- Question 2. Relative contra-indications for proceeding with TMT include which of the following?
- History of prior pelvic radiation
 - Diffuse CIS throughout the bladder
 - Tumor extending into the distal ureter which cannot be resected transurethrally
 - All of the above
- Question 3. TURBT as part of TMT includes which of the following?
- Maximal resection of all visible tumor
 - Resection of tumor just enough to prove invasion into the muscularis propria
 - Thorough resection and ablation of any adjacent field effect or associated papillary tumor
 - A and C

Trimodality therapy for muscle invasive bladder cancer – Adam Feldman, MD

- Question 1. What percentage of patients in the US undergo radical cystectomy for MIBC?
- 20%
 - 50%
 - 70%
 - 90%
- Question 2. Which of the following statements are true in patients after TMT?
- Local recurrences rarely occur
 - Any local recurrence warrants a salvage cystectomy
 - The presence of tumor associated CIS in the original tumor seems to correlate with a greater risk of local recurrence
 - Patients do not tolerate standard intravesical therapies after TMT

Cardiac Risk in Men with Erectile Dysfunction: What is the Urologist's Role? – Jared Bieniek, MD

- Question 1. Rank the arteries below by size, from smallest diameter (or most likely to manifest atherosclerotic changes earliest) to largest.
- Coronary, penile, internal carotid, femoral
 - Penile, coronary, internal carotid, femoral
 - Femoral, internal carotid, coronary, penile
 - Internal carotid, femoral, coronary, penile
- Question 2. What behavioral/dietary recommendations have been shown to potentially improve erectile function?
- Regular exercise
 - Healthy diet
 - Weight loss
 - Smoking cessation
 - All of the above

Surgical management of high-risk and metastatic prostate cancer – Isaac Kim, MD

- Question 1. What is the proven clinical effect of neoadjuvant androgen deprivation therapy?
- Improved survival
 - Decreased biochemical progression rate
 - Improved quality of life
 - Decreased surgical margin rate
- Question 2. What is the true statement regarding local therapy in men with de novo metastatic prostate cancer?
- cytoreductive surgery improves survival.
 - cytoreductive surgery is safe.
 - local radiation is effective in all men with metastatic prostate cancer.
 - local radiation is effective in men with high metastatic burden.

2025
DUES STATEMENT



To: _____
Physician's Name

Email address (please print legibly)

Annual Dues: \$200.00
January 1, 2025 - December 31, 2025

Dues exempt: Residents and Members over 67 who are fully retired and have been a member for three consecutive years.

PLEASE MAKE CHECK PAYABLE TO:

Connecticut Urology Society

Check Enclosed

Credit Card Payment

___ Visa

___ Mastercard

___ American Express

— / — / — / — / — / — / — / — / — / — / — / — / — / — / — / — /
(16 digit card number)

___ / ___ / ___
*3 digit # MC/Visa

___ / ___ / ___
(Expiration date)

___ / ___ / ___ / ___
*4 digit # American Express

Card Holders' Name

Billing Zip Code

Please return yellow copy of this statement with your payment.

Send payment to:
Connecticut Urology Society, P.O. Box 854, Litchfield, CT 06759

If you have any questions, please feel free to contact Debbie Osborn
at 860-567-3787 or email debbieosborn36@yahoo.com

Thank you.

www.cturology.org